Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter
Late-Stage Asset Attracts ‘Robust’ Investors
Executive Summary
The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.
You may also be interested in...
Lilly Looks To Complement Mounjaro, Obesity Pipeline With Versanis Buyout
Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity. This is Lilly’s fourth M&A transaction since 20 June.
Orphazyme's Arimoclomol Disappoints For Muscle-Wasting Disorder
The Danish biotech's stock sank after arimoclomol failed in a Phase II/III trial for inclusion body myositis. Orphazyme is hoping for much better news in the coming weeks as the US FDA makes its decision on the drug as a treatment for Niemann-Pick disease Type C.
Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.